On September 8, 2026, Bristol-Myers Squibb Company, E.R. Squibb & Sons, L.L.C., and Ono Pharmaceutical Co., Ltd. sued Amgen Inc. in the District of Delaware, No. 1:26-cv-01134. The plaintiffs asked for leave to file the complaint under seal. The sealed complaint is on the docket. Amgen has appeared.
What the public record shows
The Patent/Trademark Report lists U.S. Patents 8,008,449 B2; 9,856,320 B2; 10,072,082 B2; 12,590,154 B2; 12,624,107 B2; 12,590,153 B2; and 12,479,917 B2. Those are the only patent numbers confirmed on the free docket used for this page.
What we are not saying
Because the complaint is sealed, this page does not claim which Amgen product is accused or which legal pathway the plaintiffs used. Readers sometimes connect this patent family to Opdivo / PD-1 biologics disputes. That product link is not verified from the sealed complaint text here.
What to watch next
Watch for an unsealed or redacted complaint, judge assignment, and Amgen's first substantive response.